Navigation Links
Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
Date:9/6/2011

Q1 2011 89

Figure 73: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Therapy Area, 2009 – Q1 2011 90

Figure 74: Licensing Strategies in Large Pharmaceutical Companies, Bristol-Myers Squibb, Licensing Deals By Phase, 2009 – Q1 2011 91

Figure 75: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Number of Licensing Deals, 2005 – Q1 2011 92

Figure 76: Licensing Strategies in Large Pharmaceutical Companies, Boehringer Ingelheim, Licensing Deals By Value, 2005 – 2010 93

Figure 77: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, 2005 – Q1 2011 94

Figure 78: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals, By Value, 2006–2010 95

Figure 79: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Number of Licensing Deals, By Value, 2005 – Q1 2011 96

Figure 80: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Type, 2009 – Q1 2011 97

Figure 81: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Geography, 2009 – Q1 2011 98

Figure 82: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Therapy Area, 2009 – Q1 2011 99

Figure 83: Licensing Strategies in Large Pharmaceutical Companies, Merck & Co., Licensing Deals By Phase, 2009 – Q1 2011 100

Figure 84: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Number of Licensing Deals, 2005 – Q1 2011 101

Figure 85: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2006 – 2010 102

Figure 86: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Value, 2005 – Q1 2011 103
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
3. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
4. Lilly and TransPharma Medical Announce Licensing and Development Agreement
5. Genzyme and Isis Complete Licensing of Mipomersen
6. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
7. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
8. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
9. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
10. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
11. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets has announced the ... Film Industry Report 2014" report to their offering. ... Global And Chinese Medical X-Ray Film Industry Report 2014 ... state of the Global medical X-ray film industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview with Dr. ... Paddock tackles topics including main men's health concerns, ... than men, and testosterone replacement therapy, among others. In ... on Doylestown Hospital’s website, Dr. Brad Paddock says, “A ... you notice pain, bulging, or asymmetry in your lower ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Praeclarus ... Made Simple as a valuable new resource for women ... two-thirds of American women work away from their children. ... touting the benefits of breastfeeding, but often feel unsupported ... nurse their babies. With its evidence-based insights, and written ...
(Date:7/12/2014)... Augusta, GA (PRWEB) July 12, 2014 ... Nova Medical Centers, is pleased to announce that it ... , This new facility will join four Atlanta-based ... will be located at 3209 Deans Bridge Road, and ... Monday through Friday. , “With Nova’s treatment philosophy ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... 2014 (HealthDay News) -- People with the lowest incomes may ... artery disease (PAD), a new study suggests. People with ... the limbs, most often the legs. The condition causes leg ... arteries throughout the body. People with PAD have a higher ... from nearly 6,800 people with PAD who took part in ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Poor More Prone to Leg Circulation Trouble 2
... the 1960s, surgeons experimented by transplanting chimpanzee organs into humans ... received a baboon heart and survived 20 days. // Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... diabetes is important because lifestyle changes and medication can prevent ... glucose tolerance test is used to identify high-risk individuals for ... study finds a cluster of risk //factors known as metabolic ... other risk factors. ,Metabolic syndrome has been shown ...
... osteoarthritis and rheumatoid arthritis cause joint pain and //stiffness ... no effective treatment to repair damaged cartilage. ... drug to prevent the onset of arthritis. The research ... a pivotal role in the onset of the condition. ...
... births of their first two children are more likely to deliver ... the same partner.// These babies are also ... results are the same even when researchers take into account the ... of birth. ,Researchers speculate that women who change ...
... the right mattress can make a difference. //Three-quarters of physicians ... a new study says they could be wrong. The new ... pain. ,Physicians often get frustrated when patients ask ... back pain. Few studies have been done on this issue ...
... night outlawed tobacco use in the Commonwealth's restaurants, taverns, ... on Sunday liquor-store sales as the House and Senate ... ,Working until nearly midnight, lawmakers also approved a sales ... thereby pumping up the state's flagging economy, and approved ...
Cached Medicine News:Health News:Animals Can give us a second chance at life 2Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4
... world-class clinician documentation and electronic medical record ... the specific needs of intensive care units ... deep clinical functionality has secured its place ... in critical care, and its the most ...
... EncounterPRO Electronic Health Record ... System (WfMS) Specialties that ... and Immunology, Cardiology, Dermatology, ... Medicine, Neurology, Neurosurgery, Obstetrics ...
... developed a touchscreen EHR and is scheduled ... user can choose to use a mouse, ... eye contact while recording encounter results. If ... also runs on a pen tablet that ...
Dairylands Health Information Management solutions provides healthcare organizations a suite of integrated applications for managing patient records, optimizing reimbursement and regulatory complianc...
Medicine Products: